PMID: 20098570Jan 26, 2010Paper

The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.

Experimental and Clinical Cardiology
Jonathan R WalkerDavinder S Jassal

Abstract

Breast cancer, a leading cause of increased morbidity and mortality among women, overexpresses the human epidermal growth factor receptor 2 in approximately 20% to 30% of cases. Trastuzumab (Trz), a monoclonal antibody against the human epidermal growth factor receptor 2, improves survival in breast cancer patients in both the adjuvant and metastatic settings. Despite the therapeutic benefits of Trz, there is an increased incidence of cardiotoxicity, particularly when administered following anthracycline-based chemotherapy. The pathogenesis underlying Trz-mediated cardiotoxicity remains poorly understood. The present review focuses on the current understanding of Trz-mediated cardiotoxicity from both the basic and clinical science perspectives.

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Related Papers

Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography
Giuseppina MilanoGiulio Pompilio
Experimental and Clinical Cardiology
Matthew ZeglinskiPawan K Singal
Annals of Oncology : Official Journal of the European Society for Medical Oncology
L YaoYun-tao Xie
The New England Journal of Medicine
Martine J Piccart-GebhartHerceptin Adjuvant (HERA) Trial Study Team
© 2021 Meta ULC. All rights reserved